TEDDY KOSOGLOU
Pharmacy in Jamison, PA
License number
Pennsylvania RP034372R
Category
Pharmacy
Type
Pharmacist
Address
Address
Jamison, PA 18929
Personal information
See more information about TEDDY KOSOGLOU at radaris.comName
Address
Phone
Warrington, PA
2457 Primrose Ct, Jamison, PA 18929
Professional information
Combinations Of Peroxisome Proliferator-Activated Receptor (Ppar) Activator(S) And Sterol Absorption Inhibitor(S) And Treatments For Vascular Indications
US Patent:
2002015, Oct 17, 2002
Filed:
Jan 25, 2002
Appl. No.:
10/057323
Inventors:
Harry Davis - Berkeley Heights NJ, US
Teddy Kosoglou - Jamison PA, US
Gilles Picard - Brussels, BE
Teddy Kosoglou - Jamison PA, US
Gilles Picard - Brussels, BE
Assignee:
Schering Corporation
International Classification:
A61K031/397
US Classification:
514/210020
Abstract:
The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted -lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Combinations Of Nicotinic Acid And Derivatives Thereof And Sterol Absorption Inhibitor(S) And Treatments For Vascular Indications
US Patent:
2004009, May 20, 2004
Filed:
Aug 13, 2003
Appl. No.:
10/639900
Inventors:
Harry Davis - Berkeley Heights NJ, US
Teddy Kosoglou - Jamison PA, US
Michael Graziano - Scotch Plains NJ, US
Joseph Hedrick - South River NJ, US
Teddy Kosoglou - Jamison PA, US
Michael Graziano - Scotch Plains NJ, US
Joseph Hedrick - South River NJ, US
Assignee:
Schering Corporation
International Classification:
A61K031/397
US Classification:
514/210020
Abstract:
The present invention provides compositions, therapeutic combinations and methods including: (a) at least one HM74 or HM74A agonist and (b) at least one substituted azetidinone or substituted -lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Crystalline Polymorph Of A Bisulfate Salt Of A Thrombin Receptor Antagonist
US Patent:
2004017, Sep 9, 2004
Filed:
Jan 9, 2004
Appl. No.:
10/755066
Inventors:
Wenxue Wu - Princeton Junction NJ, US
Tao Wang - Springfield NJ, US
John Chiu - Parsippany NJ, US
Anastasia Pavlovsky - Morris Plains NJ, US
William Greenlee - Teaneck NJ, US
Michael Graziano - Scotch Plains NJ, US
Teddy Kosoglou - Jamison PA, US
Madhu Chintala - Colts Neck NJ, US
Samuel Chackalamannil - Califon NJ, US
Tao Wang - Springfield NJ, US
John Chiu - Parsippany NJ, US
Anastasia Pavlovsky - Morris Plains NJ, US
William Greenlee - Teaneck NJ, US
Michael Graziano - Scotch Plains NJ, US
Teddy Kosoglou - Jamison PA, US
Madhu Chintala - Colts Neck NJ, US
Samuel Chackalamannil - Califon NJ, US
Assignee:
Schering Corporation
International Classification:
C 07D 4 5/02, A61K031/4433
US Classification:
514/337000, 546/284100
Abstract:
A crystalline polymorph of a bislulfate salt of a thrombin receptor antagonist compound, which exhibits a powder x-ray diffraction profile substantially the same as that shown in FIG. , or which exhibits a differential scanning calorimtery profile substantially the same as that shown in FIG. , and is represented by the formula for Compound 2:
and processes for preparing Compound 2 are disclosed. Pharmaceutical compositions comprising the polymorph of the bisulfate salt and at least one excipient or carrier, and methods of using the polymorph of Compound 2 to treat a variety of physiological disorders, such as thrombosis, are also disclosed.
Constrained Himbacine Analogs As Thrombin Receptor Antagonists
US Patent:
7442712, Oct 28, 2008
Filed:
May 25, 2005
Appl. No.:
11/137283
Inventors:
Mariappan V. Chelliah - Edison NJ, US
Samuel Chackalamannil - Califon NJ, US
Yan Xia - Edison NJ, US
Martin C. Clasby - Plainsboro NJ, US
William J. Greenlee - Teaneck NJ, US
Yuguang Wang - North Brunswick NJ, US
Enrico P. Veltri - Princeton NJ, US
Wenxue Wu - Princeton Junction NJ, US
Michael P. Graziano - Scotch Plains NJ, US
Teddy Kosoglou - Jamison PA, US
Madhu Chintala - Colts Neck NJ, US
Samuel Chackalamannil - Califon NJ, US
Yan Xia - Edison NJ, US
Martin C. Clasby - Plainsboro NJ, US
William J. Greenlee - Teaneck NJ, US
Yuguang Wang - North Brunswick NJ, US
Enrico P. Veltri - Princeton NJ, US
Wenxue Wu - Princeton Junction NJ, US
Michael P. Graziano - Scotch Plains NJ, US
Teddy Kosoglou - Jamison PA, US
Madhu Chintala - Colts Neck NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A61K 31/44, C07D 409/00
US Classification:
514337, 5462841
Abstract:
A compound represented by the structural formulaAlso disclosed are pharmaceutical compositions and combinations containing said compounds and their uses as thrombin receptor antagonists and binders to cannabinoid receptors.
Combinations Of Sterol Absorption Inhibitor(S) With Blood Modifier(S) For Treating Vascular Conditions
US Patent:
2002014, Oct 10, 2002
Filed:
Jan 25, 2002
Appl. No.:
10/056680
Inventors:
Teddy Kosoglou - Jamison PA, US
Rudyard Ress - Flemington NJ, US
John Strony - Lebanon NJ, US
Enrico Veltri - Princeton NJ, US
Rudyard Ress - Flemington NJ, US
John Strony - Lebanon NJ, US
Enrico Veltri - Princeton NJ, US
Assignee:
Schering Corporation
International Classification:
A61K031/397
US Classification:
514/210020
Abstract:
The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor; and (b) at least one blood modifier, which can be useful for treating vascular conditions and lowering plasma levels of sterols.
Pharmacokinetically-Based Dosing Regiments Of A Thrombin Receptor Antagonist
US Patent:
2012002, Feb 2, 2012
Filed:
Nov 16, 2009
Appl. No.:
13/129725
Inventors:
Larisa Reyderman - Watchung NJ, US
Teddy Kosoglou - Jamison PA, US
Enrico P. Veltri - Princeton NJ, US
Teddy Kosoglou - Jamison PA, US
Enrico P. Veltri - Princeton NJ, US
International Classification:
A61K 31/443, A61K 31/5377, A61P 9/00, A61K 31/444
US Classification:
5142352, 514333, 514337
Abstract:
Dosing regimens based on the pharmacokinetic characteristics of a thrombin receptor antagonist are disclosed. In some embodiments, the dosing regimens result in mean plasma concentrations. Also disclosed are methods of treating acute coronary syndrome and peripheral arterial disease, and of effecting secondary prevention, by orally administering thrombin receptor antagonists according to such dosing regimens.
Combinations Of Nicotinic Acid And Derivatives Thereof And Sterol Absorption Inhibitor(S) And Treatments For Vascular Indications
US Patent:
2002018, Dec 5, 2002
Filed:
Jan 25, 2002
Appl. No.:
10/057646
Inventors:
Harry Davis - Berkeley Heights NJ, US
Teddy Kosoglou - Jamison PA, US
Teddy Kosoglou - Jamison PA, US
Assignee:
Schering Corporation
International Classification:
A61K031/397, A61K031/455
US Classification:
514/210020, 514/210040, 514/210200, 514/356000
Abstract:
The present invention provides compositions, therapeutic combinations and methods including: (a) at least one of nicotinic acid or derivatives thereof; and (b) at least one substituted azetidinone or substituted -lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Combinations Of Peroxisome Proliferator-Activated Receptor (Ppar) Activator(S) And Sterol Absorption Inhibitors(S) And Treatments For Vascular Indications
US Patent:
2008005, Mar 6, 2008
Filed:
Aug 29, 2007
Appl. No.:
11/897227
Inventors:
Harry Davis - Berkeley Heights NJ, US
Teddy Kosoglou - Jamison PA, US
Gilles Picard - Brussels, BE
Teddy Kosoglou - Jamison PA, US
Gilles Picard - Brussels, BE
International Classification:
A61K 31/397, A61P 43/00, C07D 205/00
US Classification:
514210020, 540200000
Abstract:
The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Sterol Absorption Inhibitor Compositions
US Patent:
2002019, Dec 19, 2002
Filed:
May 1, 2002
Appl. No.:
10/136968
Inventors:
Wing-Kee Cho - Princeton NJ, US
Harry Davis - Berkeley Heights NJ, US
Teddy Kosoglou - Jamison PA, US
Gilles Picard - Braine L'Alleud, BE
Harry Davis - Berkeley Heights NJ, US
Teddy Kosoglou - Jamison PA, US
Gilles Picard - Braine L'Alleud, BE
International Classification:
A61K038/43, A61K031/397
US Classification:
424/094100, 514/210020
Abstract:
The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted -lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Par-1 Antagonism In Fed Or Antacid-Dosed Patients
US Patent:
2012009, Apr 19, 2012
Filed:
Feb 9, 2010
Appl. No.:
13/148799
Inventors:
Larisa Reyderman - Watchung NJ, US
Teddy Kosoglou - Jamison PA, US
Teddy Kosoglou - Jamison PA, US
International Classification:
A61K 31/443, A61P 7/02, A61P 9/00
US Classification:
514337
Abstract:
Disclosed are methods of inhibiting a PAR-1 receptor in a patient who has recently ingested food or an antacid comprising the step of administering an effective amountand/or the bisulfate salt thereof.